Effects of hypoxia on human cancer cell line chemosensitivity

BackgroundEnvironment inside even a small tumor is characterized by total (anoxia) or partial oxygen deprivation, (hypoxia). It has been shown that radiotherapy and some conventional chemotherapies may be less effective in hypoxia, and therefore it is important to investigate how different drugs act in different microenvironments. In this study we perform a large screening of the effects of 19 clinically used or experimental chemotherapeutic drugs on five different cell lines in conditions of normoxia, hypoxia and anoxia.MethodsA panel of 19 commercially available drugs: 5-fluorouracil, acriflavine, bortezomib, cisplatin, digitoxin, digoxin, docetaxel, doxorubicin, etoposide, gemcitabine, irinotecan, melphalan, mitomycin c, rapamycin, sorafenib, thalidomide, tirapazamine, topotecan and vincristine were tested for cytotoxic activity on the cancer cell lines A2780 (ovarian), ACHN (renal), MCF-7 (breast), H69 (SCLC) and U-937 (lymphoma). Parallel aliquots of the cells were grown at different oxygen pressures and after 72 hours of drug exposure viability was measured with the fluorometric microculture cytotoxicity assay (FMCA).ResultsSorafenib, irinotecan and docetaxel were in general more effective in an oxygenated environment, while cisplatin, mitomycin c and tirapazamine were more effective in a low oxygen environment. Surprisingly, hypoxia in H69 and MCF-7 cells mostly rendered higher drug sensitivity. In contrast ACHN appeared more sensitive to hypoxia, giving slower proliferating cells, and consequently, was more resistant to most drugs.ConclusionsA panel of standard cytotoxic agents was tested against five different human cancer cell lines cultivated at normoxic, hypoxic and anoxic conditions. Results show that impaired chemosensitivity is not universal, in contrast different cell lines behave different and some drugs appear even less effective in normoxia than hypoxia.

[1]  J. Brown,et al.  Exploiting tumour hypoxia in cancer treatment , 2004, Nature Reviews Cancer.

[2]  C. Koch,et al.  Hypoxic Heterogeneity in Human Tumors: EF5 Binding, Vasculature, Necrosis, and Proliferation , 2001, American journal of clinical oncology.

[3]  Shuang-yin Han,et al.  Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. , 2008, Cancer science.

[4]  S. Wilhelm,et al.  Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. , 2006, Cancer research.

[5]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. Teicher,et al.  Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. , 1981, Cancer research.

[7]  A. Sartorelli,et al.  Generation of Oxygen Deficiency in Cell Culture Using a Two-Enzyme System to Evaluate Agents Targeting Hypoxic Tumor Cells , 2008, Radiation research.

[8]  J. Raleigh,et al.  Identification of nonproliferating but viable hypoxic tumor cells in vivo. , 1998, Cancer research.

[9]  J. Siegfried,et al.  Effects of anthracyclines on oxygenated and hypoxic tumor cells. , 1983, Cancer research.

[10]  H. S. Schwartz Pharmacology of mitomycin C. III. In vitro metabolism by rat liver. , 1962, The Journal of pharmacology and experimental therapeutics.

[11]  A. Matsumura,et al.  Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1α)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells , 2005, Journal of Cancer Research and Clinical Oncology.

[12]  S. Steinberg,et al.  Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors , 2011, Clinical Cancer Research.

[13]  S. Gamage,et al.  Structure−Activity Relationships of 1,2,4-Benzotriazine 1,4-Dioxides as Hypoxia-Selective Analogues of Tirapazamine , 2003 .

[14]  P. Vaupel,et al.  Treatment resistance of solid tumors: role of hypoxia and anemia. , 2001, Medical oncology.

[15]  M. Sekine,et al.  Vascular Endothelial Growth Factor Mediates Intracrine Survival in Human Breast Carcinoma Cells through Internally Expressed VEGFR1/FLT1 , 2007, PLoS medicine.

[16]  Peter Nygren,et al.  Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA) , 1992, International journal of cancer.

[17]  D. Scudiero,et al.  Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. , 2002, Cancer research.

[18]  M. Dewhirst,et al.  Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  S. Yang,et al.  Cobalt chloride-induced apoptosis and extracellular signal-regulated protein kinase 1/2 activation in rat C6 glioma cells. , 2004, Journal of biochemistry and molecular biology.

[20]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[21]  Corinne E Griguer,et al.  Xanthine oxidase-dependent regulation of hypoxia-inducible factor in cancer cells. , 2006, Cancer research.

[22]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[23]  Liz Y. Han,et al.  Functional significance of VEGFR‐2 on ovarian cancer cells , 2009, International journal of cancer.

[24]  Huafeng Zhang,et al.  Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization , 2009, Proceedings of the National Academy of Sciences.

[25]  B. Zetter,et al.  Angiogenesis and tumor metastasis. , 1998, Annual review of medicine.

[26]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Schmitt,et al.  Hypoxia-Inducible Factor 1α Determines Gastric Cancer Chemosensitivity via Modulation of p53 and NF-κB , 2010, PloS one.

[28]  K. Brennan,et al.  Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells. , 2012, Urologic oncology.

[29]  Meenhard Herlyn,et al.  Axis of evil: molecular mechanisms of cancer metastasis , 2003, Oncogene.

[30]  M. Gaub,et al.  Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1α Axis , 2009, Clinical Cancer Research.

[31]  I. Roninson The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. , 1992, Biochemical pharmacology.

[32]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[33]  M. Gassmann,et al.  Regulation of the multidrug resistance transporter P‐glycoprotein in multicellular tumor spheroids by hypoxia‐inducible factor‐1 and reactive oxygen species , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  J. Dorsman,et al.  Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. , 2007, Biochemical pharmacology.

[35]  C. Graham,et al.  Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1 , 2009, Molecular Cancer Therapeutics.

[36]  Jae-hoon Park,et al.  The critical role of ERK in death resistance and invasiveness of hypoxia-selected glioblastoma cells , 2009, BMC Cancer.

[37]  B. Brüne,et al.  Tumor hypoxia and cancer progression. , 2006, Cancer letters.

[38]  T. Danielsen,et al.  Hypoxia-induced changes in radiation sensitivity in human melanoma cells: importance of oxygen-regulated proteins, adenylate energy charge and cell cycle distribution. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  L. Kunz-Schughart,et al.  Multicellular tumor spheroids: an underestimated tool is catching up again. , 2010, Journal of biotechnology.

[40]  T. Cramer,et al.  Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[41]  N. Masumori,et al.  Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines. , 2008, Biomedical research.

[42]  M. Kunitama,et al.  Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan , 2009, Molecular Cancer Therapeutics.

[43]  Janice M. Y. Brown,et al.  The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. , 1999, Cancer research.

[44]  Elin Lindhagen,et al.  The fluorometric microculture cytotoxicity assay , 2008, Nature Protocols.

[45]  J. Pouysségur,et al.  Hypoxia and cancer , 2007, Journal of Molecular Medicine.

[46]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[47]  Christian Sillaber,et al.  BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. , 2002, Blood.

[48]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[49]  A. Eggermont,et al.  Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats , 1999, British Journal of Cancer.

[50]  C. Aquino-Parsons,et al.  A pilot study comparing intratumoral oxygenation using the comet assay following 2.5% and 5% carbogen and 100% oxygen. , 2001, International journal of radiation oncology, biology, physics.

[51]  H. Esumi,et al.  Hypoglycemic/hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs , 2011, Cancer science.

[52]  Jun O. Liu,et al.  Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth , 2008, Proceedings of the National Academy of Sciences.

[53]  Kwangmo Yang,et al.  The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1α expression , 2013, Oncology reports.

[54]  L. Huang,et al.  Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. , 2008, Blood.

[55]  P. Giannakakou,et al.  Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. , 2005, Cancer research.

[56]  A. Giaccia,et al.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.

[57]  C. Grau,et al.  The relationship between carbon monoxide breathing, tumour oxygenation and local tumour control in the C3H mammary carcinoma in vivo. , 1994, British Journal of Cancer.

[58]  S. Williamson,et al.  Tirapazamine: a novel agent targeting hypoxic tumor cells. , 2009, Expert opinion on investigational drugs.

[59]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[60]  Shuang-yin Han,et al.  Hypoxia‐inducible factor‐1α contributes to hypoxia‐induced chemoresistance in gastric cancer , 2007 .

[61]  C. Koch,et al.  Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. , 1995, British Journal of Cancer.

[62]  H. S. Schwartz,et al.  Pharmacology of mitomycin C. I. Toxicity and pathologic effects. , 1960, Cancer research.

[63]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[65]  Jiannis Ragoussis,et al.  Concordant Regulation of Gene Expression by Hypoxia and 2-Oxoglutarate-dependent Dioxygenase Inhibition , 2006, Journal of Biological Chemistry.

[66]  W. Figg,et al.  Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. , 1998, Biochemical pharmacology.

[67]  Y. Abe,et al.  Hypoxia-inducible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer. , 2011, Oncology reports.

[68]  R. Cardone,et al.  The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis , 2005, Nature Reviews Cancer.

[69]  B. Telfer,et al.  Hypoxia‐targeted over‐expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT‐11) , 2007, The journal of gene medicine.

[70]  I. Olver,et al.  Tirapazamine: from bench to clinical trials. , 2006, Current clinical pharmacology.

[71]  Christine C. Hudson,et al.  Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin , 2002, Molecular and Cellular Biology.

[72]  K. Kihara,et al.  Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids , 2004, Molecular and Cellular Endocrinology.

[73]  Franz Rachbauer,et al.  Differentiation of malignant and benign musculoskeletal tumors: combined color and power Doppler US and spectral wave analysis. , 2002, Radiology.

[74]  T. E. Fitzpatrick,et al.  Effect of hypoxia on cellular adhesion to vitronectin and fibronectin. , 2001, Biochemical and biophysical research communications.

[75]  T. Kwok,et al.  Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. , 1991, British Journal of Cancer.

[76]  C. Bokemeyer,et al.  Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro , 2003, British Journal of Cancer.

[77]  R. Larsson,et al.  Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system. , 2012, Experimental cell research.

[78]  D. Ribatti,et al.  Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. , 2006, Cancer research.

[79]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[80]  Crispin J. Miller,et al.  Hypoxia-Mediated Down-Regulation of Bid and Bax in Tumors Occurs via Hypoxia-Inducible Factor 1-Dependent and -Independent Mechanisms and Contributes to Drug Resistance , 2004, Molecular and Cellular Biology.

[81]  F. de Longueville,et al.  Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity , 2008, Molecular Cancer.